The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from the ABCSG-34 trial.
暂无分享,去创建一个
R. Greil | M. Gnant | Z. Bago-Horvath | P. Dubsky | C. Singer | M. Filipits | M. Balic | C. Fesl | R. Kronenwett | E. Petru | M. Rudas | D. Egle | A. Petzer | V. Wette | A. Pichler | Stephanie Meek | M. Balić
[1] R. Greil,et al. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34). , 2020, European journal of cancer.
[2] Amy M. Sitapati,et al. Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] J. Lancaster,et al. Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer , 2020, Annals of Surgical Oncology.
[4] E. Winer,et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] M. Piccart,et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. , 2019, The Lancet. Oncology.
[6] R. Greil,et al. Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2− Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only , 2019, Clinical Cancer Research.
[7] J. Cuzick,et al. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone , 2019, Breast Cancer Research and Treatment.
[8] J. Griggs,et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Amy M. Sitapati,et al. NCCN Guidelines Insights: Breast Cancer, Version 3.2018. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[10] C. Denkert,et al. Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor , 2018, Clinical Cancer Research.
[11] Amy M. Sitapati,et al. Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[12] J. Cuzick,et al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer , 2018, JAMA oncology.
[13] J. Cuzick,et al. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy , 2016, Journal of the National Cancer Institute.
[14] M. Morrow,et al. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy , 2015, Nature Reviews Clinical Oncology.
[15] E. Rutgers,et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] F. Bertucci,et al. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. , 2014, Cancer letters.
[17] Gideon Blumenthal,et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.
[18] Kelly K Hunt,et al. Neoadjuvant therapy in the treatment of breast cancer. , 2014, Surgical oncology clinics of North America.
[19] R. Greil,et al. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients , 2013, British Journal of Cancer.
[20] R. Greil,et al. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] C. Denkert,et al. Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test , 2012, BMC Cancer.
[22] H. Höfler,et al. Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay , 2012, Virchows Archiv.
[23] R. Greil,et al. A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors , 2011, Clinical Cancer Research.
[24] G. Hortobagyi,et al. Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.